Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: Safety and preliminary activity of the open-label, single-arm, phase II ARCADIA trial

被引：2

作者：

Marandino, L. ^{[1
]}

Raggi, D. ^{[1
]}

Giannatempo, P. ^{[1
]}

Calareso, G. ^{[2
]}

Alessi, A. ^{[3
]}

Colecchia, M. ^{[4
]}

Madison, R. ^{[5
]}

Ross, J. S. ^{[6
]}

Necchi, A. ^{[1
]}

机构：

[1] Ist Nazl Tumori Milano Fdn IRCCS, Dept Med Oncol, Milan, Italy

[2] Ist Nazl Tumori Milano, Fdn IRCCS, Radiol, Milan, Italy

[3] Ist Nazl Tumori Milano Fdn IRCCS, Nucl Med, Milan, Italy

[4] Ist Nazl Tumori Milano Fdn IRCCS, Pathol, Milan, Italy

[5] Fdn Med Inc, Clin Bioinformat Operat, Cambridge, MA USA

[6] Fdn Med Inc, Cambridge, MA USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.845

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

773P

引用

页码：S595 / S595

页数：1

共 50 条

[1] Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial
Marandino, L.
Raggi, D.
Giannatempo, P.
Calareso, G.
Alessi, A.
Colecchia, M.
Madison, R.
Ross, J. S.
Necchi, A.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (12) : 900 - 900
[2] Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial
Marandino, L.
Raggi, D.
Calareso, G.
Alessi, A.
Colecchia, M.
Martini, A.
Briganti, A.
Montorsi, F.
Madison, R.
Ross, J. S.
Necchi, A.
CLINICAL GENITOURINARY CANCER, 2021, 19 (05) : 457 - 465
[3] Clinical safety and activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy (ARCADIA): Preliminary results from a nonrandomized, open-label, phase 2 trial.
Giannatempo, Patrizia
Franza, Andrea
Marandino, Laura
Raggi, Daniele
Calareso, Giuseppina
Alessi, Alessandra
Colecchia, Maurizio
Bevilacqua, Liana
Russo, Giusy
Del Re, Marzia
Anichini, Andrea
Sgambelluri, Francesco
Sepe, Pierangela
Zimatore, Matteo
Claps, Melanie
Verzoni, Elena
Guadalupi, Valentina
Ottini, Arianna
Procopio, Giuseppe
Necchi, Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced and chemotherapy-treated bladder carcinoma of urothelial and non-urothelial histology: An open-label, single-arm, phase 2 trial.
Necchi, Andrea
Giannatempo, Patrizia
Raggi, Daniele
Anichini, Andrea
Calareso, Giuseppina
Crippa, Flavio
Mariani, Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[5] Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Giannatempo, P.
Bottiglieri, A.
Guadalupi, V.
Marandino, L.
Raggi, D.
Stellato, M.
Rametta, A.
Baciarello, G.
Sepe, P.
Claps, M.
Buti, S.
Pipitone, S.
Iacovelli, R.
Calareso, G.
Alessi, A.
Cattaneo, L.
Verzoni, E.
Ortega, C.
Procopio, G.
Necchi, A.
ANNALS OF ONCOLOGY, 2023, 34 : S1205 - S1205
[6] Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial.
Giannatempo, Patrizia
Guadalupi, Valentina
Marandino, Laura
Raggi, Daniele
Stellato, Marco
Rametta, Alessandro
Baciarello, Giulia
Bottiglieri, Achille
Sepe, Pierangela
Claps, Melanie
Buti, Sebastiano
Stefania, Pipitone
Iacovelli, Roberto
Calareso, Giuseppina
Alessi, Alessandra
Cattaneo, Laura
Verzoni, Elena
Procopio, Giuseppe
Mariani, Luigi
Necchi, Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the phase 2 ARCADIA trial.
Giannatempo, Patrizia
Sgambelluri, Francesco
Stellato, Marco
Guadalupi, Valentina
Raggi, Daniele
Rametta, Alessandro
Bottiglieri, Achille
Claps, Melanie
Walter, Ferrari Bravo
Oldani, Simone
Zimatore, Matteo
Calareso, Giuseppina
Alessi, Alessandra
Cattaneo, Laura
Verzoni, Elena
De Braud, Filippo G.
Procopio, Giuseppe
Necchi, Andrea
Anichini, Andrea
Mortarini, Roberta
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 684 - 684
[8] Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: The phase 2 ARCADIA trial.
Mereu, Alessandro
Salsetta, Jeannette
Lalli, Luca
Squarcina, Paola
Banfi, Cristina
Sgambelluri, Francesco
Mortarini, Roberta
Huber, Veronica
Stellato, Marco
Raggi, Daniele
Guadalupi, Valentina
Claps, Melanie
Bottiglieri, Achille
Walter, Ferrari Bravo
Calareso, Giuseppina
Alessi, Alessandra
Procopio, Giuseppe
Necchi, Andrea
Rivoltini, Licia
Giannatempo, Patrizia
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 687 - 687
[9] Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients
Tomita, Yoshihiko
Tatsugami, Katsunori
Nakaigawa, Noboru
Osawa, Takahiro
Oya, Mototsugu
Kanayama, Hiroomi
Kondoh, Chihiro Nakayama
Sassa, Naoto
Nishimura, Kazuo
Nozawa, Masahiro
Masumori, Naoya
Miyoshi, Yasuhide
Kuroda, Shingo
Tanaka, Shingo
Kimura, Akiko
Tamada, Satoshi
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (11) : 952 - 959
[10] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
Huang, X.
Shen, J.
Xiong, Y.
Wang, Y.
Cao, X.
He, M.
Zou, G.
Deng, Y.
Wang, X.
Lan, C.
GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43

← 1 2 3 4 5 →